

CURRICULUM VITAE-Daniel B. Ornt. MD

CURRICULUM VITAE

Daniel Burrows Ornt, M.D., F.A.C.P.

May 5th, 2013

Personal

Home Address: 23Arthurian Way
North Chili, NY 14514

Office Address: College of Health Sciences & Technology
Rochester Institute of Technology
153 Lomb Memorial Drive, CBET-3183
Rochester, NY 14623

Home/Cell Phone: 216-849-1286

Office Phone: 585-475-4017

Office Fax: 585-475-4330

E-mail Address: Daniel.ornt@rit.edu

Date of Birth: January 21, 1951

Education – Undergraduate

Year	Degree	Institution and Location
1973	B.A. (Natural Science and Chemistry)	Colgate University Hamilton, New York

Education – Graduate

Year	Degree	Institution and Location
1976	M.D.	School of Medicine and Dentistry University of Rochester Rochester, New York

Postdoctoral Training

Year	Position	Institution and Location
6/1976 to 6/1977	Intern	Department of Medicine Medical Center Hospital of Vermont College of Medicine University of Vermont Burlington, Vermont
7/1977 to 6/1979	Resident	Department of Medicine Medical Center Hospital of Vermont College of Medicine University of Vermont Burlington, Vermont

CURRICULUM VITAE-Daniel B. Ornt. MD

7/1979 to 6/1980	Clinical Fellow	Division of Nephrology Department of Medicine University Hospital University of Michigan Ann Arbor, Michigan
7/1980 to 6/1981	Research Fellow	Division of Nephrology Department of Medicine University Hospital University of Michigan Ann Arbor, Michigan

Licensure and Certification

<u>Year</u>	<u>License/Certification</u>	
9/1979	American Board of Internal Medicine	
11/1982	Subspecialty Boards, Nephrology	
1995-2003	UNOS Transplant Physician, Kidney and Liver	
4/1981	New York State License	145780
11/2003-2012	Ohio License	83541

Faculty Appointments

1/1/13 to 2018	Clinical Professor of Medicine School of Medicine and Dentistry University of Rochester
12/1/11 to date	Professor of Health Sciences with Tenure Rochester Institute of Technology
7/1/08 to date	Professor of Medicine and Anatomy School of Medicine Case Western Reserve University
5/15/04 to 6/08	Professor of Medicine School of Medicine Case Western Reserve University
10/01/03 to 5/15/04	Visiting Professor of Medicine School of Medicine Case Western Reserve University

CURRICULUM VITAE-Daniel B. Ornt. MD

1/1/04 to 12/31/04	Adjunct Professor of Medicine School of Medicine and Dentistry University of Rochester
11/30/02 to 12/31/03	Professor of Medicine and Pediatrics with Tenure School of Medicine & Dentistry University of Rochester
11/1/97 to 11/1/02	Professor of Medicine and Pediatrics School of Medicine & Dentistry University of Rochester
7/1/88 to 10/31/97	Associate Professor of Medicine and Pediatrics School of Medicine & Dentistry University of Rochester
5/1/84 to 6/30/88	Assistant Professor of Medicine and Pediatrics School of Medicine & Dentistry University of Rochester
7/1/82 to 4/30/84	Assistant Professor of Medicine School of Medicine & Dentistry University of Rochester
7/1/81 to 6/30/82	Senior Instructor of Medicine School of Medicine & Dentistry University of Rochester

Administrative Appointments

12/1/11 to date	Vice President, Institute of Health Sciences & Technology Dean, College of Health Sciences & Technology Rochester Institute of Technology
8/10/10 to 11/30/11	Director, Center for Medical Education School of Medicine Case Western Reserve University
7/1/08 to 11/30/11	Interim Chair, Department of Anatomy School of Medicine, Case Western Reserve University
7/1/06 to 11/30/11	Vice Dean for Education and Academic Affairs School of Medicine Case Western Reserve University

CURRICULUM VITAE-Daniel B. Ornt. MD

4/14/04 to 6/30/06	Associate Dean for Clinical Affairs School of Medicine Case Western Reserve University
8/15/00 to 9/30/03	Vice Chair, Department of Medicine School of Medicine & Dentistry University of Rochester
7/1/02 to 5/31/03	Acting Chief, Allergy/Immunology/Rheumatology School of Medicine & Dentistry University of Rochester
5/1/98 to 8/14/00	Associate Chair for Clinical Services, Department of Medicine School of Medicine & Dentistry University of Rochester
2/1/00 to 9/1/01	Acting Chief, Division of Gastroenterology School of Medicine & Dentistry University of Rochester
10/1/99 to 9/30/03	Associate Program Director, GCRC School of Medicine & Dentistry University of Rochester
1997-1998	Acting Director, Medical Renal Transplantation Strong Memorial Hospital 601 Elmwood Avenue Rochester, NY 14642
1996 to 9/30/03	Medical Director, Lake Plains Dialysis Center, Medina Memorial Hospital 200 Ohio Street Medina, NY 14103
12/23/91 to 7/1/99	Director, Clinical Nephrology School of Medicine & Dentistry University of Rochester
10/1/88 to 9/1/98	Medical Director of Dialysis Strong Memorial Hospital Rochester, NY 14642
7/1/88 to 8/25/89	Acting Chief, Division of Nephrology School of Medicine & Dentistry University of Rochester
1983-1992	Medical Director of Peritoneal Dialysis Strong Memorial Hospital 601 Elmwood Avenue Rochester, NY 14642

CURRICULUM VITAE-Daniel B. Ornt. MD

University and Hospital Committees

2011	Chair Search Committee, Department of Otolaryngology, CWRU and UHCMC
2010	Chair Search Committee, Department of Medicine, CWRU and MetroHealth Director Search, Center for Advancement of Medical learning, CWRU SOM Chair, Search Committee
2009	Chair Search, Department of Pathology School of Medicine, Case Western Reserve University Faculty Search – Medical Education Assessment School of Medicine, Case Western Reserve University Chair, Search Committee
2008 to 2011	Board of Directors University Hospital Medical Group Case Medical Center
2007 to 2011	Dean’s Leadership Committee, CWRU Case Medical Center Oversight Committee Case Western Reserve University Clinical Chairs’ Council University Hospitals University Outcome Assessment Committee Case Western Reserve University Chair Search, Department of Radiation Oncology School of Medicine, Case Western Reserve University Chair Search, Department of Pediatrics School of Medicine, Case Western Reserve University Chair Search, Department of Radiology School of Medicine, Case Western Reserve University Quality Committee – Dean’s Representative University Hospitals of Cleveland Chair Search, Department of Urology School of Medicine, Case Western Reserve University Chair Search, Department of Neurology School of Medicine, Case Western Reserve University

CURRICULUM VITAE-Daniel B. Ornt. MD

2006	<p>Strategic Academic Plan Committee Case Western Reserve University</p> <p>Chair Search, Department of Environmental Health School of Medicine, Case Western Reserve University, Committee Chair</p> <p>Search Committee – Associate Chief of Staff/Research Louis Stokes Cleveland Department of Veterans Affairs Medical Center</p> <p>Center for Diabetes Research, Education and Patient Care Case Western Reserve University and University Hospitals of Cleveland</p>
2005	<p>Search Committee – Mount Sinai Skills & Simulation Center Faculty Director School of Medicine Case Western Reserve University</p> <p>Search Committee – Edgar B. Jackson Endowed Chair School of Medicine Case Western Reserve University</p>
2004	<p>Clinical Council of Chairs – Dean’s Representative University Hospitals of Cleveland</p> <p>Board of Directors – Dean’s Representative MetroHealth System</p> <p>Dean’s Advisory Committee – Mount Sinai Skills & Simulation Center; Chair School of Medicine Case Western Reserve University</p> <p>Dean’s Working Group – Mount Sinai Skills & Simulation Center; Chair School of Medicine Case Western Reserve University</p> <p>Information Technology Subcommittee – Mount Sinai Skills & Simulation Center; Chair School of Medicine Case Western Reserve University</p> <p>Ohio Deans’ Council Representative for Case Western Reserve University</p> <p>Search Committee – Department of Surgery Chair School of Medicine, Case</p> <p>Veterans Affairs Dean’s Committee; Chair Louis Stokes Cleveland VA Medical Center Case Western Reserve University</p>

CURRICULUM VITAE-Daniel B. Ornt. MD

School of Medicine & Dentistry University of Rochester

1991-1995	Department of Medicine QA Committee
10/91	Search Committee – Chief of Endocrinology School of Medicine & Dentistry University of Rochester
7/1/96 to 9/30/03	Medicine Program Council; Chair School of Medicine & Dentistry University of Rochester
1997-1999	R-1 Selection Committee; Member School of Medicine & Dentistry University of Rochester
1/99 to 9/03	SMH Clinical Council University of Rochester
8/00 to 9/03	Risk Management Committee School of Medicine & Dentistry University of Rochester
1/01 to 9/03	URFMG Finance Committee University of Rochester
1/01 to 9/03	Medical Center Board of Directors – Elected Member University of Rochester
3/01 to 9/03	Medical Center Board of Directors – Development Committee University of Rochester
1/99 to 9/03	Medical Center Board of Directors – Joint Quality of Care Committee University of Rochester
11/99	Search Committee, Chief of Gastroenterology School of Medicine & Dentistry University of Rochester
5/01	Search Committee, Chair of Radiology School of Medicine & Dentistry University of Rochester

CURRICULUM VITAE-Daniel B. Ornt. MD

Hospital Appointments

4/14/04 to 11/30/11	Attending Physician in Medicine and Nephrology University Hospitals of Cleveland 11100 Euclid Avenue Cleveland, OH 44106
12/1/03 to 11/30/11	Louis Stokes veterans Administration Hospital Cleveland, OH Administrative member
7/1/81 to 12/31/03	Attending Physician in Medicine Strong Memorial Hospital 601 Elmwood Avenue Rochester, NY 14642
5/1/84 to 12/31/03	Attending Physician in Pediatrics Strong Memorial Hospital 601 Elmwood Avenue Rochester, NY 14642
1988-1997	Chairman, Dialysis and Transplant Committee Strong Memorial Hospital 601 Elmwood Avenue Rochester, NY 14642
9/15/83 to 12/31/90	Attending Physician Regional Kidney Services Center 335 Mt. Vernon Avenue Rochester, NY 14620
7/1/88 to 12/31/91	President of Medical Staff Regional Kidney Services Center 335 Mt. Vernon Avenue Rochester, NY 14620
2/1/91 to 9/30/03	Attending Physician in Dialysis Highland Hospital of Rochester 1000 South Avenue Rochester, NY 14620

Awards and Honors: National

10/09	IHI and Macy Foundation Project: Retooling for Quality Team Co-Leader
-------	--

CURRICULUM VITAE-Daniel B. Ornt. MD

5/2009	Millennium Conference 2009, Shapiro Institute, Harvard University Team Leader
1/1999	American College of Physicians – Elected directly to Fellow
7/1/80 to 6/30/81	Smith, Kline & French Research Fellow National Kidney Foundation University of Michigan
7/87	American Society of Nephrology Travel Award To the Meeting of the International Society of Nephrology London, England
2/89	Kidney Foundation Visiting Professor Upstate Medical Center Syracuse University Division of Nephrology
1998-2011	The Best Doctors in America, National edition
11/98	Distinguished Service Award National Kidney Foundation, Inc. Nat

Awards and Honors: Local and Regional

Class of 1973	Proctor and Gamble Scholar Colgate University
7/1/72 to 8/31/72	Summer Fellow in Biomedical Research for Premedical Students School of Medicine & Dentistry University of Rochester
7/82 to 6/83 & 7/83 to 6/84	Buswell Fellowship Department of Medicine University of Rochester
1989-1990	Faculty Service Award Department of Pediatrics University of Rochester
6/92	Volunteer Service Award National Kidney Foundation of Upstate New York
1996-2003	Best Doctors in America, Northeast Region
1997	The Gift of Life Award National Kidney Foundation of Upstate New York
2003	NFF Upstate New York Named-ORNT Educational Seminar Series

CURRICULUM VITAE-Daniel B. Ornt. MD

2009	Scholarship in Teaching Award, School of Medicine, CWRU
2009	Ralph Horwitz Partnership Award, Cleveland Public Schools

Professional Organizations and Societies

National and International

2004 to date	Society for Medical Simulation
1999 to date	American College of Physicians, Fellow
1995 to 2005	American Physiological Society
1994-1996	National Kidney Foundation Nominating Committee, MAB
1995-1996	National Kidney Foundation Council on Dialysis Executive Committee
1995-1996	American College of Physician Executives
	American Federation for Clinical Research
	American Society of Nephrology International Society of Nephrology
	Forum of End Stage Renal Disease Networks New York State Network Representative
	International Society of Peritoneal Dialysis
	Renal Physicians Association
	Society for Clinical Trials

State and Local

7/86 to 6/88	National Kidney Foundation of Upstate New York Chairman, Medical Advisory Board
7/86 to 1995	National Kidney Foundation of Upstate New York Member Executive Committee
7/88 to 1998	National Kidney Foundation of Upstate New York Member, Board of Directors

CURRICULUM VITAE-Daniel B. Ornt. MD

11/91	National Kidney Foundation of Upstate New York Chair, Executive Director Search Committee
1988 to 1991	National Kidney Foundation of Upstate New York Member, Research Grant Review Committee
1992-1994	National Kidney Foundation of Upstate New York Vice President, Board of Directors
1994-1996	National Kidney Foundation of Upstate New York President, Board of Directors
10/96 to 9/03	ESRD Network of New York, Inc. Vice President and Secretary
7/90 to 9/03	ESRD Network of New York, Inc. Council Member
7/92 to 9/01	ESRD Network of New York, Inc. Medical Review Board
1/94 to 9/03	ESRD Network of New York, Inc. Chair , Research and Education Committee
1996 to 9/03	ESRD Network of New York, Inc. Executive Committee
1989-1994	Kidney Foundation of Central Pennsylvania Outside Research Grant Reviewer
10/01 to 10/02	National Kidney Foundation (NKF) Regulatory & Reimbursement Forum Co-Chair
11/01 to 11/02	First Health Services Corporation Physicians advisory panel representative of local practice perspectives in the State of New York

Research Education

2007 to 2011	Research and Scholarship – Medical Student Thesis Oversight Committee, Case Western Reserve University
7/1/97 to 6/30/99	Fellow sponsor: Suresh Sankarasubbaiyan, M.D. Clinical Research Fellow, University of Rochester
7/1/97 to 6/30/98	Fellow sponsor: Sai Subhodhini Reddy, M.D. Clinical Research Fellow University of Rochester

CURRICULUM VITAE-Daniel B. Ornt. MD

7/1/86 to 6/30/87	Medical Student co-sponsor: Deborah Khani NIH: Year-Out Research Fellowship University of Rochester
7/1/82 to 6/30/83	Fellow sponsor: John D. Scandling, M.D. Research Fellow Kidney Foundation of Upstate New York University of Rochester

Research and Educational Funding Experience

National and Local Funding – Previous

7/10 to 12/11	Interprofessional Learning Exchange and Development Program: Josiah Macy Jr. Foundation, Co-Leader, \$640,000
7/10-12/11	Health Professional Pipeline Program: Joan C. Edwards Charitable Foundation and Case Western Reserve University, Administrative Director (no salary) \$10M
7/1/06 to 9/30/10	RMPHEC (Public Health in Medical Education) AAMC and CDC PI: Total Award \$150,000
7/06 to 6/10	Quality Improvement and Patient Safety in Medical Education; Prentiss Foundation of Cleveland, PI \$1M
10/1/03 to 9/30/10	Daily Dialysis Multi-center Clinical Trial, PI-Nathan Levin, MD Consultant NIDDK, UO1
6/1/05 to 6/30/10	Program for Health Care Quality and Safety Elisabeth Severance Prentiss Foundation, Cleveland, OH 5% effort PI: Total Award \$1 Million
6/1/05 to 6/30/12	Mt. Sinai Skills & Simulation Center at Case Western Reserve University Mt. Sinai Health Care Foundation, Cleveland, OH Co-PI. Total Award \$5 Million No salary
10/1/03 to 9/30/06	The Clinical Transaction Development Pathway NA % effort PI. Total Award \$150,000

CURRICULUM VITAE-Daniel B. Ornt. MD

10/1/99 to 9/30/03	NIH, NCRR GCRC PI – David Guzick, M.D., Ph.D. Position: Associate Program Director, 25% effort
9/30/94 to 8/31/03	NIH-NIDDK Hemodialysis (HEMO) Study PI – Clinical Center, NIH;UO-1; Total Award \$1,700,000
9/23/85 to 8/31/88	NIH-New Investigator Research Award Mechanism of K depletion in chronic metabolic acidosis PI. Total Award \$106,000
7/1/85 to 6/30/87	American Heart Association Grain-In-Aid Mechanism of Cyclosporin-induced hyperkalemia PI. Total Award \$66,690

Previous Clinical Trials

1996-1998	Premiere Research Worldwide
1998-1999	Hoechst Marion Roussel
1999	Amgen Study
1999	Parke-Davis Study
2002-2003	PharmaNet Study-Kremezin

Previous Local Research Awards

4/1/83 to 3/31/85	Rochester Eye and Human Parts Bank Mechanism of hyperkalemia in metabolic acidosis PI. Total Award \$18,000
7/1/84 to 6/30/85	Genesee Valley Chapter American Heart Association Role of aldosterone in hypokalemia during metabolic acidosis PI. Total Award \$9,000.00
7/1/84 to 6/30/85	Kidney Foundation of Upstate New York Mechanism of Cyclosporin-induced hyperkalemia PI. Total Award \$6,000.00

Pending Awards

2/2013	NSF Geriatric Adoption of New Technology Products and services SP 1%, PI J. Ettlie
--------	--

CURRICULUM VITAE-Daniel B. Ornt. MD

Major Education and Teaching Responsibilities

Medical School

2011	Case IQ Group Faculty Block 5, August/September Foundations of Clinical Medicine, year 1 Panel discussion – Conflict of Interest, April
2010	Case IQ Group Faculty Block 5, August/September Foundations of Clinical Medicine, year 1 Panel discussion – Conflict of Interest, March 30 th
2009	Case IQ Group Faculty, Block 5, August/September
2008	Case IQ Group Faculty, Block 4, May External Curriculum Review- Chair- June
2007 to present	Joint Clinical Oversight Group, CWRU, member Student Assessment Committee, CWRU, member Student Advisory Committee, CWRU, member
2006 to present	Thirteen Schools' Steering Committee, member for CWRU Committee on Medical Education, CWRU, ex-officio Committee on Students, CWRU, ex-officio Curriculum Monitoring Council - Chair
2004-2006	Dean's Curriculum Development Committee, CWRU, member
1999	New Curriculum Development, Module B, University of Rochester
1985 to 2003	Renal Physiology – First Year Students; Conference Leader for Problem Sets and Laboratory Section
1988 to 2003	Renal Pathology – Second Year Students; Introductory Lecture (1988-1999), PBL (2000-01)

University Hospitals and Department of Medicine

2010	Nephrology Fellows Conference – Pericarditis- April 30 th
2004 to present	Graduate Medical Education Committee, University Hospitals, member
2003-2006	Nephrology Resident Lectures, University Hospital, Acute Renal Failure, monthly
1982 to 2003	Medical Attending and Student Preceptor; six weeks per year
1981 to 2003	House-staff Conferences on Nephrology Topics, yearly

CURRICULUM VITAE-Daniel B. Ornt. MD

Clinical Responsibilities at CWRU

2003 to 2011 Cleveland Dialysis Centers, Rounding Nephrologist
Weekly rounds 45 patients

University Hospitals of Cleveland, Inpatient Renal Service
May 2007 and February 2008, 2009, 2010, 2011

University Hospitals of Cleveland, General Inpatient Medicine
May 2005 and 2006

Manuscript Reviews

American Journal of Kidney Disease

Journal American Society of Nephrology

Kidney International

Nephrology, Dialysis and Transplant

National Committees

11/2010 USMLE Writing Committee – Patient Safety

2011-2012 Governing Council, Section on Medical Schools
AMA – elected June 2011

7/2010 NIDDK, SBI Grants
Scientific Review Committee, Chair

2007-08 NIDDK, NIH
Scientific Review, Ad Hoc – Chair for review

2006-07 National Board of Medical Examiners, Co-Chair
Special Writing Committee, Case Patient Safety Collaborative

2006-07 NIDDK, NIH
Scientific Reviewer – 10-06

2005-06 NIDDK, NIH
Scientific review – ad hoc

6/95 to 6/99 NCRR, NIH. Clinical Research Centers
Study Section

CURRICULUM VITAE-Daniel B. Ornt. MD

1999-2000	NCRR, NIH. Clinical Research Centers Ad hoc reviewer
10/98 & 10/02	American Society of Nephrology, Program Committee for Hemodialysis Adequacy
3/00	New York State Governmental Task Force on ESRD Invited Member
7/01	NIDDK, NIH Ad hoc Study Section
3/00	New York State Governmental Task Force on ESRD Invited Member
12/03	NIDDK, NIH Ad hoc Study Section
12/04	NIDDK, NIH Ad hoc Study Section
5/04	The American Assembly – Untangling the Healthcare Quality Knot: Frontline Perspectives Invited Steering Committee Member

State Committees

2006-07	Ohio Physician Supply and Demand Committee, consultant Ohio Board of Regents
2004 to present	Ohio Council of Deans Case Western Reserve University representative
2009-10	Medical School Metrics for Board of Regents Sub-committee for Ohio Council of Deans
2008	Scope of Practice Committee Ohio State Medical Board
2009/2010	Education Metrics Committee Ohio Council of Deans

Invited Presentations/Lectures/Participations since 2002

10/11/02	ESRD Network of New York, Inc. Annual Scientific Program HEMO Study: Primary Results
----------	---

CURRICULUM VITAE-Daniel B. Ornt. MD

11/2/02	American Society of Nephrology Annual Meeting Cardiovascular Disease Outcome: HEMO Study
3/15/03	Department of Medicine Grand Rounds, University of Rochester End Stage renal Disease-Can Hemodialysis Improve?
10/17/05	2005 Ohio Health Information Symposium NetWellness.com 1995-2005: Ten Years of Experience
10/28/05	American College of Physicians 2005 Ohio Chapter Scientific Meeting Update in Nephrology
11/22/05	University Hospitals of Cleveland Medical Grand Rounds Chronic Hemodialysis: Can Outcome Be Improved?
2/21/07	Western Reserve2 Curriculum RMPHEC Annual Meeting, AAMC Miami, FL.
6/23/07	Lerner College of Medicine and Western Reserve2 Curriculum at CWRU AMA Annual Meeting, Section on Medical Schools, Chicago IL.
11/2/08	e-Folios in Medical Education, Presentation and Panel AAMC Annual Meeting, San Antonio, TX
4/16/09	Outcomes in Hemodialysis, Renal Clinical Conference, University Hospitals of Cleveland, Cleveland, OH
5/6/09	Student Portfolios in Medical Education, Medicine Grand Rounds, Alleghany General Hospitals, Pittsburgh, PA
5/6/09	Hemodialysis Outcomes – Can They Improve? Nephrology Conference, Alleghany General Hospital, Pittsburgh, PA.
2/5/10	Admissions Perspective: What Are SOMs Looking For? Michael J Wolk Conference 2010, Colgate University, Hamilton, NY
9/20/10	New Horizons in Medical Education: AMA and AAMC: invited participant
1/14/11	Frequent Hemodialysis – Clinical Outcomes. College of Medicine, Howard University, Washington, DC,
4/5/11	Improved Outcomes with Daily Hemodialysis. Medical Grand Rounds, University Hospitals Case Medical Center.
7/21/11	Interprofessional Education: A focus for Schools of Medicine and Nursing, AARP Webinar series. Project with Robert Wood Johnson Foundation.
12/6/12	An example of the challenge of implementation of research-proven therapies (<i>Lost in Translation</i>). <i>Liberty Hill Breakfast Presentation</i> , President's House, Rochester, NY

Publications

Manuscripts and Chapters

1. Arceci R, Garver G, Dean V, Dukes C, Ornt D, Rothfus W, and Szymanski H. A comparative study of medical care of patients with stroke. Chapter 10 in Berg RL, Brooks MR, Jr, and Savicevic M. Health Care in Yugoslavia and the United States. Fogarty International Proc. No. 34, NIH, 1976.
2. Ornt DB and Tannen RL. Demonstration of an intrinsic renal adaptation for K⁺ conservation in short term K⁺ depletion. Am J Physiol. 245:F329-F338, 1983.
3. Berg RL and Ornt DB. End stage renal disease: How many, how much? Am J Pub Health. 74:4-5, 1984.
4. Ornt DB. Effect of potassium concentration and ouabain on the renal adaptation to potassium depletion in isolated rat kidney. Can J Physiol Pharmacol. 64:1427-1433, 1986.
5. Ornt DB and Scandling JD. Disorders of potassium balance. Chapter 3 in Humes, HD (ed), Pathophysiology of Electrolyte and Renal Disorders. Churchill – Livingstone, Inc. 1986.
6. Scandling JD and Ornt DB. Mechanism of potassium depletion during chronic metabolic acidosis. Am J Physiol. 252:F122-F130, 1987.
7. Ornt DB, Scandling JD and Tannen RL. Adaptation for potassium conservation during dietary potassium deprivation. Semin Nephrol.VII: 193-205, 1987.
8. Chormann ML, Staccone M, Edd P, Andrus CH and Ornt DB. Experience with Automated peritoneal dialysis (APD) in a pediatric population. Advances in Continuous Peritoneal Dialysis. pp 66-72, 1987.
9. Feld LG, Malek RS, Ornt DB and Greenfield SP. Consequences of urinary tract infections in childhood. In Current Nephrology. HC Gonick (ed). Vol. 12, 1988.
10. Scandling, JD, Izzo JL, Jr., Pabico RC, McKenna BA, Radke RJ and Ornt DB. Potassium Homeostasis during angio-converting enzyme inhibition with enalapril. J Clin Pharmacol. 29:916-921, 1989.
11. Batsford KC and Ornt DB. Hemolytic uremic syndrome. Kidney and Urology Facts. National Kidney Foundation, Inc, 1991.
12. Ornt DB, Griffin PM, Wells JG and Powell KR: Hemolytic uremic syndrome due to Escherichia coli 0157:H7 in a child with multiple infections. Pediatr Nephrol 6:270-272, 1992.
13. Ornt DB. Book Review: Principles and Practice of Nephrology, eds. Jacobson, Striker, and Klahr 1991. N Engl J Med. 326:422, 1992.

14. Mansoor GA Panner BJ and Ornt DB. Azithromycin-induced acute interstitial nephritis. *Ann Intern Med* (Letter) 119:636-637, 1993.
15. Avissar N, Ornt DB, Yagil Y, Horowitz S, Watkins RH, Kerl EA, Takahashi K, Palmer IS, and Cohen H: Glutathione peroxidase in plasma originates from human kidney proximal tubular cells. *Am J Physiol* 266:C367-C375, 1994.
16. Mansoor GA and Ornt DB. Cryptococcal peritonitis in peritoneal dialysis patients: A case report. *Clin Nephrol* 41:230-232, 1994.
17. Eknayan G, Levey AS, Beck GJ, Agodoa LY, Daugirdas JT, Kusek JW, Levin NW, Schulman G, HEMO Study Group: the Hemodialysis (HEMO) Study: Rationale for selection of interventions. *Sem Dialysis* 9:24-33, 1996.
18. Ornt DB, Radke KJ and Scandling JD. Effect of aldosterone on renal potassium conservation in the rat. *Am J Physiol* 270:E1003-E1008, 1996.
19. HEMO Study Group, prepared by Daugirdas JT, Depner TA, Gotch FA, Greene T, Keshaviah P, Levin NW, and Schulman G. Comparison of methods to predict equilibrated Kt/V in the HEMO Pilot Study. *Kidney Int* 52:1395-1405, 1997.
20. HEMO Study Group, prepared by Leypoldt JK, Cheung AK, Agodoa YC, Daugirdas JT, Greene T, Keshaviah PR. Hemodialyzer mass transfer-area coefficients for urea increase at high dialysate flow rates. *Kidney Inter* 51:2013-2017, 1997.
21. Whitin JC, Tham DM, Bhamre S, Ornt DB, Scandling JD, Tune BM, Salvatierra O, Avissar N, and Cohen HJ. Plasma glutathione peroxidase and its relationship to renal proximal tubule function. *Molecular Genetics and Metabolism* 65:238-245, 1998.
22. HEMO Study Group, prepared by Depner TA, Greene T, Gotch FA, Daugirdas JT, Keshaviah PK, Star RA. Imprecision of the hemodialysis dose when measured directly from urea removal. *Kidney Inter* 55:635-647, 1999.
23. HEMO Study Group, Cheung AK, Agodoa LY, Daugirdas JT, Depner TA, Gotch FA, Greene T, Levin NW, Leypoldt JK. Effects of hemodialyser reuse clearances of urea and B2-microglobulin. *J Am Soc Neph* 10:117-127, 1999.
24. Uribarri J, Levin NW, Delmez J, Depner TA, Ornt D, Owen W, Yan G. Association of acidosis and nutritional parameters in hemodialysis patients. *Am J Kidney Dis* 34:493-499, 1999.
25. Allon M, Ornt D, Schwab S, Rasmussen C, Delmez J, Kusek J, Martin A, Minda S and the Hemodialysis (HEMO) Study Group. Factors associated with the prevalence of A-V fistulas in hemodialysis patients in the HEMO Study. *Kidney Inter* 58:2178-2185, 2000.
26. Reddy SS, Ornt DB. Permanent dialysis access placement in pre-ESRD patients: The relation to patient characteristics. *Dialysis Transplantation* 30: 142-166, 2001.

CURRICULUM VITAE-Daniel B. Ornt. MD

27. Miskulin DC, Athienites NV, Yan G, Martin AA, Ornt DB, Kusek JW, Meyer KB, Levey AS and the HEMO Study Group. Comorbidity assessment using the index of coexistent disease (ICED) in a multicenter clinical trial: The Hemodialysis (HEMO) Study. *Kidney Inter* 60:1498-1510, 2001.
28. Rocco M, Yan G, Gassman JJ, Lewis JB, Ornt DB, Weiss B, Levey AS and the HEMO Study Group. Comparison of causes of death using HEMO Study and HCFA ESRD death notification classification systems. *Am J Kidney Dis* 39:146-153, 2002.
29. Cheung AK, Yan G, Greene T, Daugirdas, JT, Dwyer JT, Levin NW, Ornt DB, Scgulman G, Eknoyan G and the HEMO Study Group. Seasonal variations in clinical and laboratory parameters in chronic hemodialysis patients. *J Am Soc Nephrol* 13:2345-2352, 2002.
30. Ornt DB. Health quality information for ESRD and public choice. *Dialysis Transplantation*. (Letter) *Dialysis and Transplant*, October, 2001.
31. Rocco MV, Yan G, Heyka RJ, Benz R, Cheung AK and the HEMO Study Group. Risk factors for hypertension in chronic hemodialysis patients: baseline data from the HEMO study. *Am J Nephrol* 21:280-288, 2001.
- 32.. Beddhu S, Kaysen GA, Yan G, Sarnak M, Agodoa L, Ornt D, Cheung AK and the HEMO Study Group. Hypoalbuminemia represents an atherosclerotic milieu in chronic hemodialysis patients. *Am J Kidney Dis*, 40:721-727, 2002.
33. Eknoyan G, Beck, GJ, Cheung AK, Daugirdas, JT, Greene T, Kusek, JW, Allon M, Bailey J, Delmez, JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, and Toto R, for HEMO Study Group. Effect of dialysis dose and membrane flux on morbidity and mortality in chronic hemodialysis patients: Primary results of the HEMO study. *N Engl J Med* 347:2010-2019, 2002.
34. Cheung AK, Levin NW, Greene T, Agodoa L, Bailey J, Beck G, Clark W, Levey AS, Leygoldt JK, Ornt DB, Rocco MV, Schulman G, Schwab ST, Teehan B, Eknoyan G, for the HEMO Study. Effect of high-flux hemodialysis on clinical outcomes: Results of the HEMO study. *J Am Soc Nephrol* 14:3251-3263, 2003.
35. Allon M, Depner TA, Radeva M, Bailey J, Beddhu S, Butterly D, Coyne DW, Gassman JJ, Kaufman AM, Kaysen GA, Lewis JA, Schwab SJ and the HEMO Study Group. Impact of dialysis dose and membrane on infection-related hospitalization and death: results of the HEMO study. *J Am Soc Nephrol*. 14:1863-1870, 2003.
36. Unruh M, Yan G, Radeva M, Hays RD, Benz R, Athienites NV, Kusek J, Levey AS, Meyer KB, and the HEMO Study Group. Bias in assessment of health-related quality of life in a hemodialysis population: a comparison of self-administered and interviewer-administered surveys in the HEMO study. *J Am Soc Nephrol* 14:2132-2141, 2003.
37. Cheung AK, Sarnak M, Yan G, Berkoben M, Heyka R, Kaufman A, Lewis J, Rocco M, Toto R, Windus D, Ornt D, Levey AS, for the HEMO Study Group. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO study. *Kidney Inter* 65: 2380-2389, 2004.

38. Bozorgzadeh A, Jain A, Ryan C, Ornt D, Zand M, Mantry P, Lansing K, Orloff M. Impact of Hepatitis C viral infection in primary cadaveric liver allograft versus primary living-donor allograft in 100 consecutive liver transplant recipients receiving tacrolimus. *Transplantation* 77: 1066-1070, 2004.
39. Rocco MV, Dwyer JT, Larive B, Greene T, Cockram DB, Chumlea WC, Kusek JW, Leung J, Burrowes JD, McLeroy SL, Poole D, Uhlin L, HEMO Study Group. The effect of dialysis dose and membrane flux on nutritional parameters in hemodialysis patients: results of the HEMO Study. *Kidney Inter* 65: 2321-2334, 2004.
40. Unruh M, Benz R, Greene T, Yan G, Beddhu S, DeVita M, Dwyer JT, Kimmel PL, Kusek JW, Martin A, Rehm-McGillicuddy J, Teehan BP, Meyer KB, HEMO Study Group. Effects of hemodialysis dose and membrane flux on health-related quality of life in the HEMO Study. *Kidney Inter* 66: 355-366, 2004.
41. Kaysen GA, Dubin JA, Muller HG, Roalae L, Levin NW, Mitch WE and the HEMO Study Group NIDDK. Inflammation and reduced albumin synthesis associated with stable decline in serum albumin in hemodialysis patients. *Kidney Inter* 65:1408-1415, 2004.
42. Unruh M, Miskulin D, Yan G, Hays RD, Benz R, Kusek JW, Meyer KB and the HEMO Study Group. Racial differences in health-related quality of life among hemodialysis patients. *Kidney Inter* 65:1482-1491, 2004.
43. Rocco MV, Cheung AK, Greene T, Eknayan G, HEMO Study Group. The HEMO Study: applicability and generalizability. *Nephrol Dial Transplant* 20: 278-284, 2005.
44. Allon M, Radeva M, Bailey J, Beddhu S, Butterly D, Coyne DW, Depner TA, Gassman JJ, Kaufman AM, Kaysen GA, Lewis JA, Schwab SJ, HEMO Study Group. The spectrum of infection-related morbidity in hospitalized haemodialysis patients. *Nephrol Dial Transplant* 20: 1180-1186, 2005.
45. Greene T, Daugirdas J, Depner T, Allon M, Beck G, Chumlea C, Delmez J, Gotch F, Kusek JW, Levin N, Owen W, Schulman G, Star R Toto R, Eknayan G; Hemodialysis Study group. Association of achieved dialysis dose with mortality in the hemodialysis study: an example of “dose-targeting bias”. *J Am Soc Nephrol* 16:3372-3380,2005.
46. Allon M, Radeva M, Bailey J, Beddhu S, Butterly D, Coyne DW, Depner TA, Gassman JJ, Kaufman AM, Kaysen GA, Lewis JA, Schwab SJ and the HEMO Study Group. The spectrum of infection-related morbidity in hospitalized hemodialysis patients. *Nephrol Dialysis Transplant* 20:1180-1186, 2005.
47. Cheung AK, Rocco MV, Yan G, Leypoldt JK, Levin NW, Greene T, Agodoa L, Bailey J, Beck G, Clark W, Levey AS, Ornt DB, Schulman G, Schwab S, Teehan B, Eknayan G, for the HEMO Study Group. Serum Beta-2-Microglobulin levels predict mortality in dialysis patients: results of the HEMO study. *J Am Soc Nephrol* 17:546-555, 2006
- 48.. Allon M, Daugirdas J, Depner TA, Greene T, Ornt D, Schwab SJ for the HEMO Study Group. Effect of change in vascular access on patient mortality in hemodialysis patients. *Am J Kidney Dis*. 47:469-477,2006.

CURRICULUM VITAE-Daniel B. Ornt. MD

49. Kilger A and FHN Study Group. High frequency hemodialysis: Rationale for the randomized clinical trials. Clin J Am Soc Nephrol. 2:390-392, 2007.
50. Suri RS, Garg AX, Chertow GM, Levin NW, Rocco MV, Greene T, Beck GJ, Gassman JJ, Eggers PW, Star RA, Ornt DB, Kliger AS. Frequent Hemodialysis Network (FHN) randomized trials study design. Kidney Intern:71, 349-359, 2007
51. Ornt DB, Aron DC, King NB, Clementz LM, Frank S, Wolpaw T, Wilson-Delfosse A, Wolpaw D, Allan TM, Carroll M, Thompson-Shaheen K, Altose MD, Horwitz RI. Population medicine in a curricular revision at Case Western Reserve University School of Medicine. Academic Med 83: 327-331, 2008.
52. GreeneT, Daugirdas JT, Depner TA, Gotch F, Kuhlman M, and Frequent Hemodialysis Network Study Group; National Institute of Diabetes and Digestive and Kidney Diseases. Solute clearances and fluid removal in the frequent hemodialysis network trials. Am J Kidney Dis 53:835-844, 2009.
53. Wolpaw TM, Hull AL, Wilson-Delfosse AL, Dannefer EF, Wolpaw DR, Isaacson JH, Papp KK, Bierer SB, Ornt DB. Case Western Reserve University School of Medicine and Cleveland Clinic. Acad Med. 85 (Suppl 9):S439-45, 2010.
54. Chertow GM, Levin NW, Beck GJ, Depner TA, Eggers PW, Gassman JJ, Gorodetskaya I, Greene T, James S, Larive B, Lindsay RM, Mehta RL, Miller B, Ornt DB, Rajagopalan SJ, Rastog A, Rocco MV, Schiller B, Sergeyeva O, Schulman G, Ting GO, Unruh ML, Star RA and Kliger AS for the FHN Trial Group. Effects of frequent in-center hemodialysis: The Frequent Hemodialysis Network Daily Trial. N Engl J Med 363:2287-2300, 2010.
55. Kaysen GA, Larive B, Painter P, Graig A, Lindsay RM, Rocco MV, Daugirdas JT, Schulman G, Chertow GM; FHN Trial Group. Baseline physical performance, health, and functioning of participants in the Frequent Hemodialysis Network (FHN) trial. Am J Kidney Dis 57: 101-112,2011.
56. Rocco MV, Larive B, Eggers PW, Beck GJ, Chertow GM, Levin NW, Kliger AS; FHN Trial Group. Baseline characteristics of participants in the Frequent Hemodialysis Network (FHN) daily and nocturnal trials. Am J Kidney Dis 57:90-100, 2011.
57. Rocco MV, Lockridge Jr, RS, Beck GJ, Eggers PW, Gassman JJ, Greene T, Larive B, Chan CT, Chertow GM, Copland M, Hoy C, Lindsay RM, Levin NW, Ornt DB, Pierratos A, Pipkin M, Rajagopalan S, Stokes JB, Unruh ML, Star RA and Kliger AS for the FHN Trial Group. Effects of nocturnal home hemodialysis: The Frequent Hemodialysis Network Nocturnal Trial. Kidney Inter 80:1080-1091, 2011.
58. Yeun JY, Ornt DB, Depner TA. Hemodialysis, Chapter 64, Taal MW, Chertow GM, Skorecki MK, Yu ASL, eds. Brenner & Rector The Kidney, Elsevier/Saunders, 9th ed, Dec. 2011,

59. Shastri S, Tangri N, Tighiouart H, Beck GJ, Vlagopoulos P, Ornt D, Eknayan G, Kusek JW, Herzog C, Cheung AK, Sarnak MJ. Predictors of sudden death: a competing risk approach in the hemodialysis study. Clin J Am Soc Nephrol 7(1):123-130, 2012.
60. Daugirdas JT, Chertow GM, Larive B, Pierratos A, Greene T, Ayus JC, Kendrick CA, James SH, Miller BW, Schulman G, Salusky IB, Klinger AS and the FHN Trial Group. Effects of frequent hemodialysis on measures of CKD mineral and bone disorder. J Am Soc Nephrol 23(4):727-738, 2012.
61. Daugirdas JT, Greene T, Rocco MV, Kaysen GA, Depner TA, Levin NW, Chertow GM, Ornt DB, Raimann JG, Larive B, Klinger AS, and the FHN Trial Group. Effect of frequent hemodialysis on residual kidney function: Frequent Hemodialysis Network (FHN) Trials. Kidney Inter 83:949-958, 2013.
62. Suri RS, Larive B, Sherer S, Eggers P, Gassman J, James SH, Lindsay RM, Lockridge RS, Ornt DB, Rocco MV, Ting GO, Klinger AS, Frequent Hemodialysis Network Trial Group. Risk of vascular access complications with frequent hemodialysis: results from the Frequent Hemodialysis Network Trials. J Am Soc Nephrol 24(3):498-505, 2013.
63. Ornt DB, Larive B, Rastogi A, Rashid M, Daugirdas JT, Hernandez A, Tamura MK, Suri R, Levin NW, Klinger AS, and the Frequent Hemodialysis Network Trial Group. Impact of Frequent Hemodialysis on Anemia Management: Results from the Frequent Hemodialysis Network (FHN) Trials. Nephrol Dialysis Transpl in press 2013.

Abstracts

1. Ornt DB and Tannen RL. Role of tissue potassium in potassium conservation. Clin Res 29:473A, 1981.
2. Ornt DB and Tannen RL. Intrinsic renal adaptation to K⁺ depletion. Proc Annual Meeting Am Soc Nephrol 14th, Wash. DC 156A, 1981 (presented).
3. Ornt DB and Kleiman F. Renal adaptation to potassium (K⁺)depletion is independent of tissue K⁺. Eastern Section AFCR, Boston MA. October 1982. Clin Res 30:703A, 1982 (presented).
4. Scandling JD and Ornt DB. Chronic metabolic acidosis inhibits renal adaptation to potassium depletion. Eastern Section AFCR, Boston, MA. October, 1983. Clin Res 31:700A, 1983 (presented).
5. Mehta RL and Ornt DB. Antithymocyte globulin (ATGAM) improves graft survival of steroid resistant rejections. Submitted to the XXI Congress of the EDTA-European Renal Association, 1984 (presented).
6. Ornt DB and Scandling JD. Renal adaptation for potassium conservation. Fed Proc 44:1913, 1985 (presented).
7. Scandling JD and Ornt DB. Cyclosporin A-induced hyperkalemia in the rat. Kidney Int 29:435, 1986 (presented).
8. Ornt DB and Scandling JD. Potassium depletion during chronic metabolic acidosis in the rat is secondary to aldosterone. Fed Proc 45:1005, 1986 (presented).
9. Scandling JD, Ornt DB, Pabico RC, McKenna BA, Radke KJ and Izzo JL, Jr. Potassium Homeostasis during angiotensin-converting-enzyme inhibition with enalapril in man. Kidney Int 31:216, 1987 (presented).
10. Chorman ML, Staccone M, Edd P and Ornt DB. Experience with automated peritoneal dialysis (APD) in a pediatric population. Am J Kidney Dis 8:A4, 1986 (presented).
11. Ornt DB and Scandling JD. Effect of aldosterone on renal adaptation to K⁺ depletion. Xth Int Congress of Nephrol 578, 1987 (presented).
12. Izzo JL, Jr, Khani DE, Scandling JD and Ornt DB. Calcium (Ca⁺⁺) channel blockade vs. variation in extracellular Ca⁺⁺: hemodynamic and natriuretic differences in the isolated rat kidney. Xth Int Congress Nephrol, 559, 1987 (presented).
13. Ornt DB and Scandling JD. Plasma magnesium (Mg⁺⁺) controls renal Mg⁺⁺ conservation during short-term. Kidney Inter 33:345, 1988 (presented).

CURRICULUM VITAE-Daniel B. Ornt. MD

14. Scandling, JD and Ornt DB. Short-term cyclosporin A treatment does not lead to urinary Magnesium wasting in the rat. Am Soc Transplant Physicians 7th Annual Meet, Chicago, June 1988 (presented).
15. Ornt DB, Griffin PM, Wells JG, and Powell KR: Hemolytic uremic syndrome in a child with varicella, Salmonella, polymicrobial septicemia and E. coli 0157:H7. J Am Soc Nephrol 2:310, 1991.
16. Ornt DB, Talley T, Panner B, Varade W, and Krassner M: A family with idiopathic focal segmental glomerulosclerosis with renal failure in two males early in life. J Am Soc Nephrol 2:258, 1991.
17. Ornt DB and Wage R: Comparison of rates of peritonitis in CAPD versus CCPD patients. 12th Annual Meeting on Peritoneal Dialysis, Feb., 1992 (presented).
18. Ornt DB: Volumetric control of ultrafiltration reduces the rate of hypotension on hemodialysis. Am Soc Nephrol, Ann Meeting, Nov., 92.
19. Cohen HJ, Avissar N, Yagil Y, Ornt DB, Bushinsky DA, and Palmer IS: Effect of nephrectomy and renal transplantation on serum glutathione peroxidase activity. Fed Proc 6:A1397, 1992 (presented).
20. Avissar N, Ornt DB, Yagil Y, Horowitz S, Watkins RH, Kerl EA, Takahashi K, Palmer IS, and Cohen H: Glutathione peroxidase activity in human plasma originates mainly from kidney proximal tubular cells. Fed Proc 1993 (presented).
21. Ornt DB and Mansoor GA. Failed treatment of disseminated *Cryptococcus neoformans* with peritonitis in a CAPD patient despite Amphotericin B, Flucytosine, and catheter removal. Perit Dial Int 13:S63, 1993.
22. Ornt DB, Avissar N, Whitin J, and Cohen HJ: Plasma glutathione peroxidase activity post renal transplant. J Am Soc Nephrol (ABSTRACT) 4:953, 1993.
23. Ornt DB, Avissar N, Whitin J, Anders MW, and Cohen HJ: Glutathione peroxidase secretion by proximal tubular cells. J Am Soc Nephrol (ABSTRACT) 4:905, 1993.
24. HEMO Study Group, (Eknoyan G, Beck GJ, Kusek JW, Levey AS, Levin NW, Ornt DB, Owen WF, Schulman G: Design, characterization of prevalent patients, and progress of the Hemodialysis (HEMO) study. American Society of Nephrology, Annual Meeting, Nov. 5, 1995 (presented).
25. Kusek JW, Beck GJ, Eknoyan G, Levey AS, Levin NW, Ornt DB, Owen WF, Schulman G from the HEMO Study Group: Representativeness of clinical trial participants: The hemodialysis study. Society for Clinical Trials Seventeenth Annual Meeting, May, 1996 (presented).
26. Ornt DB, Kusek J, Dockery J, Martin A, Minda S, Weiss B, Yanchar K, and the HEMO Study Group, National Institutes of Health, Bethesda, Maryland, Assessment of data quality in an NIH-sponsored multicenter clinical trial: The hemodialysis (HEMO) study: Soc Clin Trials, 2nd Joint Meeting, Boston, MA, July, 1997 (presented).

CURRICULUM VITAE-Daniel B. Ornt. MD

27. Weiss B, Levey A, Breyer J, Drabik M, Gassman J, Ornt D, Rocco M, and the HEMO Study Group, Cleveland Clinic Foundation, Cleveland, Ohio. Use of volunteer physicians for outcome review in the hemodialysis (HEMO) study. Soc Clin Trial, 2nd Joint Meeting, Boston, MA July, 1997 (presented).
28. Ornt DB, Panner BJ and Waring S. Analysis of cause of death determination in the end-stage renal disease program. J Am Soc Nephrol 8:207A, 1997 (presented).
29. Levey AS, Athienites NV, Gassman JJ, Martin AA, Ornt DB, Kusek JW, and Meyer KB. Comorbidity assessment in the hemo study: An interim report. J Am Soc Nephrol 8:201A, 1997 (presented).
30. Uribarri J, Levin N, Delmez J, Depner T, Ornt D, Owen W and Yan G. Association of acidosis and nutritional parameters in hemodialysis patients. J Am Soc. Nephrol 8:108A, 1997 (presented).
31. Lilley S and Ornt DB. Are patients willing to receive erythropoietin subcutaneously despite being on hemodialysis? ESRD Network #2 of New York, Inc., Annual Meeting, Oct., 1997, (presented).
32. Delmez J, Agodoa L, Ornt D, Beck G and HEMO Study Group. Effects of Gluteraldehyde, formaldehyde and renalin on β_2 -microglobulin (β_2 M) clearances in high flux dialyzers reprocessed with bleach. J Am Soc Neph 9:296A, 1998, (presented).
33. Leypoldt J, Cheung A, Daugirdas J, Greene T, Levin N, Ornt D, Schulman G, and HEMO Study Group. Evaluation of Hemodialyzer (HD) clearance(K) of β_2 M using predialysis and postdialysis plasma concentrations. J Am Soc Neph 9:299A, 1998, (presented).
34. Sankarasubbaiyan S, Monk R, Holley J, Ornt D. Prevalence and severity of hypomagnesemia in renal transplant recipients on tacrolimus. J Am Soc Neph 9:715A, 1998.
35. Reddy SS and Ornt DB. Permanent access placement in our pre-ESRD patient. J Am Soc Neph 10:216A, 1999.
36. Allon M, Ornt DB, Schwab SJ, Delmez J, Kusek JA, Martin AA, Minda S, Rasmussen C. Factors determining the prevalence of A-V fistulas (AVF) in hemodialysis (HD) patients in the HEMO Study. J Am Soc Neph 10:200A, 1999.
37. Cheung A, Daugirdas J, Dwyer J, Greene T, Levin N, Ornt D, Schulman G, Yan G, Eknoyan G, and HEMO Study Group. Seasonal variations (SV) in clinical and laboratory parameters in chronic hemodialysis (HD) patients. J Am Soc Neph 10:236A, 1999.
38. Rocco MV, Yan G, Gassman J, Lewis J, Ornt D, Weiss B, Levey AS for the HEMO Study Group. A comparison of causes of death in the HEMO Study with the HCFA death notification form. J Am Soc Neph 10:254A, 1999 (presented).
39. Greene T, Daugirdas J, Beck G, Depner T, Ornt D, Schulman G, Star R, Eknoyan G and the HEMO Study Group. Effect of variability on performance standards for achieving a minimum spKt/V goal. J Am Soc Neph 10:330A, 1999 (presented).

40. Ornt D, Greene T, Kaufman A, Minda S, Rehm-McGillicuddy J, Weiss B, Kusek J and the HEMO Study Group. Measurement of adherence in a hemodialysis (HD) therapy clinical trial: Assessment of prescribed HD dose on sampling versus non-sampling days. *Controlled Clinical Trials* 21:93S, 2000 (presented).
41. Schulman G, Delmez J, Greene T, Kimmel P, Martin A, Ornt D, Levey N, Levin N. Experience with Two Dialyzers in Series (2-DS) in the HEMO Study. *J Am Soc Neph* A0942, 11:177A, 2000 (presented).
42. Beddhu S, Kaysen G, Yan G, Sarnak M, Agodoa L, Ornt D, Cheung AK, and the HEMO Study Group. Hypoalbuminemia (hypoalb) Represents an Atherosclerotic Milieu in Hemodialysis (HD) Patients. *J Am Soc Neph* A1349, 11:256A, 2000 (presented).
43. Rocco M, Owen W, Greene T, Radeva M, Delmez J, Kaufman A, Kusek J, Ornt D, Eknoyan, and the HEMO Study Group. Predictors of Elevated C-Reactive Protein (CRP) Levels in Chronic HD Patients Results from the HEMO Study. *J Am Soc Neph* A1864, 12362A, 2001 (presented).
44. Cheung AK, Agodoa L, Daugirdas JT, Greene T, Levey AS, Milford E, Ornt D, Rocco M, Sarnak M, Yan G, Eknoyan G & HEMO Study Group. Predictive value of blood pressure for mortality in chronic hemodialysis patients changes with duration of follow-up. *J Am Soc Neph* 2003 (presented).
45. Daugirdas J, Allon M, Depner, T, Greene T, Ornt D, Schwab, S, and the HEMO Study Group. Effect of Change in Vascular Access Status on Outcome in the HEMO Study. *J Am Soc Neph* A, 2003 (presented).
46. Marine S, Embi PJ, Wentz S, Pirie P, Ornt DB, McCuistion M, Haag, D, Guard R. NetWellness 1995-2005: Ten Years of Experience and Growth as a Non-Profit Consumer health Information and Ask-an-Expert Service. *Ohio Health Information Symposium 2005* (presented).
47. Wentz S, Embi PJ, Marine S, Pirie P, Ornt DB, Haag D, McCuistion M, Guard R. NetWellness 1995-2005: Ten Years of Experience: An Ohio Health Internet Service Serving a National and Global Audience. *Ohio Health Information Symposium 2005* (presented).
48. Papp KK, Stager M, Montgomery L, Wolpaw TM, Medvedev I, Nosek TM, Ornt DB. Education in the Clinical Transaction: A Learner-Centered Approach. *Association of American Medical Colleges, Innovations in Education Exhibit 2005* (presented).
49. FHN Trial Group. The Frequent Hemodialysis Network multicenter randomized trial of in-center daily dialysis. *American Society of Nephrology*, October 2006 presented.
50. Hyson AM, Scott S, Papp KK, Marina O, Stulberg J, Wilson-Delfosse A, Wolpaw TM, Ornt, DB, Altose M, Wolpaw DR. The Western Reserve2 Curriculum: Evaluating change. *Soc Gen Intern Med*, April 2007, presented.

51. Chertow GM, Levin NW, Beck GJ, Depner TA, Eggers PW, Gassman JJ, Gorodetskaya I, Greene T, James S, Larive B, Lindsay RM, Mehta RL, Miller B, Ornt DB, Rajagopalan SJ, Rastog A, Rocco MV, Schiller B, Sergeyeva O, Schulman G, Ting GO, Unruh ML, Star RA and Klinger AS for the FHN Trial Group. Effects of frequent in-center hemodialysis: The Frequent Hemodialysis Network Daily Trial. Late Breaking Clinical Trials- American Society of Nephrology, Denver, CO; Nov. 19, 2010-presented.
52. Ornt DB, Larive B, Rashid MA, Daugirdas J, Hernandez A, Rastogi A, Tamura M, Suri R, Klinger AS, and Levin N. The Impact of Frequent versus Conventional Hemodialysis (HD) on Anemia Management in Patients with End-Stage Renal Disease (ESRD): The Frequent HD Network (FHN) Trial. American Society of Nephrology, Philadelphia PA 2011, presented.
53. Suri R, Larive B, Sherer SG, Gassman JJ, Ornt DB, Rocco MV, James SH, Lindsay RM, Ting GO, Eggers PW, Klinger AS, The FHN Trial Group. Risk of vascular access events in the FHN Daily Trial. Am Soc Nephrol, Annual Meeting, oral presentation, Nov. 2011.
54. Daugirdas JT, Greene TH, Rocco MV, Kaysen GA, Depner TA, Levin NW, Chertow, GM, Ornt DB, Raimann JG, Larive, B, Klinger AS, FHN Trial Group. Effect of frequent dialysis on residual kidney function in the Frequent Hemodialysis Network Nocturnal and Daily Trials. Annual Meeting- Am Soc Nephrol, November 2012, presented.